Latest Information
Below you can access the latest press releases, financial reports, corporate governance documents and more. Please note that some documents may refer to Liminal BioSciences' previous name Prometic Life Sciences Inc.
-
Liminal BioSciences Reports Fourth Quarter and Year End 2020 Financial Results
Liminal BioSciences Reports Fourth Quarter and Year End 2020 Financial Results
-
Liminal BioSciences Provides Update on Business Strategy and Focus on Small Molecule Therapeutics
LMNL focused on continued advancement of its small molecule therapeutics platform including development of fezagepras and evaluating strategic alternatives for its plasma-derived therapeutics entity.
-
Liminal BioSciences Receives FDA Approval for its US-based Plasma Collection Center
Prometic Plasma Resources (USA) Inc., has received U.S. Food and Drug Administration (“FDA”) approval for its plasma collection center located in Amherst, NY.
-
Liminal BioSciences Announces First Subject Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras
LMNL today announced that the first subject has been dosed in the Company’s fezagepras Phase 1 multiple ascending dose clinical trial in healthy volunteers.
-
Press Releases
Read More -
Annual Report 2020
-
Quarterly Report Q3 2020
-
Quarterly Report Q2 2020
-
Financial Reports
Read Now -
Board Committees - Chairs' Mandate 2020
-
Mandate of the Chair of the Board 2020
-
LMNL Share Price
View Now -
CEO Position Description 2020
-
Corporate Governance
Read More -
Loading More...